Overcoming obstacles to repurposing for neurodegenerative disease

Annals of Clinical and Translational Neurology

Volumn 1, Issue 7, 2014, Pages 512-518

  Shineman, Diana W ^a   Alam, John ^b   Anderson, Margaret ^c   Black, Sandra E ^d   Carman, Aaron J ^a   Cummings, Jeffrey L ^e   Dacks, Penny A ^a   Dudley, Joel T ^f   Frail, Donald E ^g   Green, Allan ^h   Lane, Rachel F ^a   Lappin, Debra ⁱ   Simuni, Tanya ^j   Stefanacci, Richard G ^k   Sherer, Todd ^l   Fillit, Howard M ^a  

^a Alzheimers Drug Discovery Foundation   (United States)

^b EIP Pharma LLC   (United States)

^c Faster Cures   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e LERNER RESEARCH INSTITUTE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g ASTRAZENECA   (United Kingdom)

^h SDG LLC   (United States)

ⁱ FaegreBD Consulting   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k Access Group   (United States)

^l THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL DEVELOPMENT PLAN; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DRUG REPOSITIONING; HEALTH CARE COST; HUMAN; MORNING SICKNESS; MULTIPLE SCLEROSIS; PATENT; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS;

EID: 84907202317     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.76     Document Type: Article

References (14)

1. Suthram S, Dudley JT, Chiang AP, et al. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput Biol 2010;6:e1000662.
2. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;3:96ra76.
3. Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011;3:96ra77
4. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203–214.
5. Thayer A. Drug repurposing. Chem Eng News 2012;90:15–25.
6. Barratt MJ, Frail DE (eds.). Repositioning drug bringing new life to shelved assets and existing drugs. Hoboken, NJ: John Wiley and Sons, Inc.; 2012.
7. Gaudry KS. Evergreening: a common practice to protect new drugs. Nat Biotechnol 2011;29:876–878.
8. Mrowietz U, Altmeyer P, Bieber T, et al. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 2007;5:716–717.
9. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004;1:101–110.
10. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314–322.
11. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124–134.
12. NCATS. Available at http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/rescue-repurpose.html (accessed 29 May 2014).
13. TLOC. Available at http://hdl.loc.gov/loc.uscongress/legislation.113hr3116 (accessed 29 May 2014).
14. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012;91:426–437.